A detailed history of Verition Fund Management LLC transactions in Bio Atla, Inc. stock. As of the latest transaction made, Verition Fund Management LLC holds 42,200 shares of BCAB stock, worth $74,272. This represents 0.0% of its overall portfolio holdings.

Number of Shares
42,200
Holding current value
$74,272
% of portfolio
0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.37 - $3.92 $57,814 - $165,424
42,200 New
42,200 $57,000
Q2 2023

Aug 14, 2023

BUY
$2.83 - $3.87 $51,777 - $70,805
18,296 New
18,296 $54,000

Others Institutions Holding BCAB

About BioAtla, Inc.


  • Ticker BCAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,304,100
  • Market Cap $63.9M
  • Description
  • BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ...
More about BCAB
Track This Portfolio

Track Verition Fund Management LLC Portfolio

Follow Verition Fund Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Verition Fund Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Verition Fund Management LLC with notifications on news.